Geode Capital Management
JSPR icon

Geode Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Geode Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Sell
263,808
-53,869
-17% -$40.3K ﹤0.01% 4077
2026
Q1 		$278K Buy
317,677
+105,820
+50% +$147K ﹤0.01% 3809
2025
Q4 		$388K Buy
211,857
+81,002
+62% +$163K ﹤0.01% 3685
2025
Q3 		$312K Sell
130,855
-275
-0.2% -$834 ﹤0.01% 3788
2025
Q2 		$728K Sell
131,130
-132,554
-50% -$653K ﹤0.01% 3431
2025
Q1 		$1.13M Buy
263,684
+5,997
+2% +$39.9K ﹤0.01% 3261
2024
Q4 		$5.51M Buy
257,687
+271
+0.1% +$5.64K ﹤0.01% 2697
2024
Q3 		$4.84M Sell
257,416
-2,338
-0.9% -$46.6K ﹤0.01% 2774
2024
Q2 		$5.9M Buy
259,754
+131,763
+103% +$3.16M ﹤0.01% 2634
2024
Q1 		$3.76M Buy
127,991
+37,543
+42% +$667K ﹤0.01% 2855
2023
Q4 		$714K Hold
90,448
– – ﹤0.01% 3475
2023
Q3 		$633K Sell
90,448
-6,102
-6% -$74.5K ﹤0.01% 3511
2023
Q2 		$1.32M Sell
96,550
-10,481
-10% -$156K ﹤0.01% 3249
2023
Q1 		$1.94M Buy
107,031
+94,289
+740% +$1.74M ﹤0.01% 3044
2022
Q4 		$60K Sell
12,742
-31
-0.2% -$208 ﹤0.01% 4542
2022
Q3 		$100K Hold
12,773
– – ﹤0.01% 4578
2022
Q2 		$246K Hold
12,773
– – ﹤0.01% 4139
2022
Q1 		$453K Buy
12,773
+1,068
+9% +$48.1K ﹤0.01% 3980
2021
Q4 		$918K Buy
+11,705
New +$1.1M ﹤0.01% 3763
2021
Q1 		– Sell
-2,563
Closed -$258K – 4458
2020
Q4 		$258K Sell
2,563
-787
-23% -$78.3K ﹤0.01% 3805
2020
Q3 		$331K Hold
3,350
– – ﹤0.01% 3567
2020
Q2 		$335K Hold
3,350
– – ﹤0.01% 3503
2020
Q1 		$319K Buy
+3,350
New +$328K ﹤0.01% 3409

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management's JSPR Position: Q2 2026 in Review

Geode Capital Management reduced its Jasper Therapeutics (JSPR) stake by 17% in Q2 2026, selling an estimated $40.3K and leaving 263,808 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #4077.

Geode Capital Management first reported a position in JSPR in Q1 2020 and has held it in 23 quarters since. The position peaked at $5.9M in Q2 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Geode Capital Management held 263,808 shares of Jasper Therapeutics worth $111K as of Q2 2026.
  • Geode Capital Management sold 53,869 Jasper Therapeutics shares in Q2 2026, an estimated $40.3K.
  • Jasper Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4077 holding.
  • Geode Capital Management first reported a position in Jasper Therapeutics in Q1 2020 and has held it in 23 quarters since.
  • Geode Capital Management's Jasper Therapeutics position peaked at $5.9M in Q2 2024.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.